Mr. Mahbubul Alam

BEXIMCO PHARMACEUTICALS LTD.

9th June, 2014

Mr. Mahbubul Alam

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; LSE-AIM: BXP) is sad to announce the death of Mr. Mahbubul Alam who passed away on Friday 6th June, 2014. He had served as a Non-Executive Independent Director of the Company from March 2014. Additionally, he was the Chairman of the Audit Committee.

Ahmed Sohail Fasiur Rahman, Chairman of Beximco Pharmaceuticals, said: "The Board of Directors recall with appreciation and gratitude Mr. Mahbubul Alam's contribution towards Beximco Pharmaceuticals Ltd during his short tenure as a Non-Executive Independent Director. The Beximco Pharma Family extends their deepest sympathy and sincerest condolences to the bereaved members of his family at his sad demise."

For further information please visit www.beximco-pharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

Daniel Stewart & Company (NOMAD and Broker)

Emma Earl

Paul Shackleton

Tel: +44 (0)20 7776 6550

FTI Consulting

Simon Conway/ Victoria Foster-Mitchell

Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.